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Aims Statins have modest adverse effects on glycaemic control. Alirocumab, a proprotein convertase subtilisin/kexin type 9
inhibitor, lowers low-density lipoprotein cholesterol. This study assessed the effects of alirocumab on new-onset
diabetes and pre-diabetes incidence in individuals without diabetes at baseline.
Methods
and results
Pooled analysis of 10 ODYSSEY Phase 3 trials (n ¼ 4974) of 24–104 weeks duration. Six trials (n ¼ 4211) were ≥52
weeks in length. Most patients received background maximally tolerated statin. Alirocumab effect on the rate of dia-
betes-related treatment-emergent adverse events (TEAEs), and/or fasting plasma glucose (FPG) and glycated haemo-
globin A1C (HbA1C) was measured at baseline and every 12–24 weeks. Transition to diabetes analysis combined TEAE
and FPG/HbA1C laboratory data. At baseline, 30.7% of individuals had diabetes and were excluded from the current
analysis. The remaining 3448 individuals without diabetes had pre-diabetes (39.6%) or were normoglycaemic
(29.7%). The hazard ratio (HR; 95% confidence interval) for diabetes-related TEAEs in alirocumab was 0.64 (0.36–
1.14) vs. placebo and 0.55 (0.22–1.41) vs. ezetimibe. The HR associated for transition from pre-diabetes to new-onset
diabetes for alirocumab was 0.90 (0.63–1.29) vs. placebo and 1.10 (0.57–2.12) vs. ezetimibe. Mean change in FPG/
HbA1C over time showed no difference between treatment groups in patients without diabetes.
Conclusions There was no evidence of an effect of alirocumab on transition to new-onset diabetes in 3448 individuals without
diabetes at baseline with a follow-up period of 6–18 months, compared to either placebo or ezetimibe. Longer
follow-up with larger number of individuals is needed to conclusively rule out an effect.
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Introduction
Recent evidence suggests that statin therapy increases the rate of
transition to diabetes.1 – 5 In those receiving rosuvastatin 20 mg in
the JUPITER (Justification for Use of statins in Prevention: an
Intervention Trial Evaluating Rosuvastatin) study,3,4 there was a
28% excess risk of diabetes (hazard ratio [HR] 1.28, 95% confidence
interval [CI] 1.07–1.54, P ¼ 0.01) compared with placebo. The ex-
cess risk of diabetes occurred only in those with one or more risk
factors for developing diabetes; no increase in diabetes was
* Corresponding author. University of Edinburgh, Institute of Molecular Medicine, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK. Tel: +44 131 651 8500,
Email: helen.colhoun@igmm.ed.ac.uk
& The Author 2016. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which
permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact
journals.permissions@oup.com
European Heart Journal
doi:10.1093/eurheartj/ehw292
 European Heart Journal Advance Access published July 26, 2016
 by guest on A
ugust 9, 2016
http://eurheartj.oxfordjournals.org/
D
ow
nloaded from
 
observed in those individuals without a major diabetes risk factor
(HR 0.99, 95% CI 0.45–2.21, P ¼ 0.99).4 Since the initial JUPITER re-
port, several meta-analyses reported a small increase in the risk of
statin-associated diabetes.1,5 Although most reports conclude that
the cardiovascular (CV) and mortality benefits from statin therapy
outweigh the diabetes hazard, the US Food and Drug Administra-
tion (FDA) implemented safety label changes stating increase in gly-
cated haemoglobin A1C (HbA1C) and fasting plasma glucose (FPG)
levels with statin use.6 Meanwhile, the exact mechanism of the
statin-associated glycaemic effect is not understood raising the
question of whether such an effect will pertain for other low-density
lipoprotein cholesterol (LDL-C) lowering drugs.7 –10
Alirocumab is a fully human proprotein convertase subtilisin/kex-
in type 9 (PCSK9) monoclonal antibody that lowers LDL-C levels
by increasing the number of low-density lipoprotein receptors
(LDLRs).11 Alirocumab reduces LDL-C by up to 61% as monother-
apy or in addition to statins, with or without other lipid-lowering
therapy (LLT) in Phase 3 studies and is now approved by the FDA
and European Medicines Agency (EMA) for use in hypercholester-
olemia patients who require additional lowering of LDL-C in adjunct
to diet and maximally tolerated statin therapy12–18 In the US, aliro-
cumab is indicated additionally in patients with clinical atheroscler-
otic CV disease, while the EMA has approved the use of alirocumab
in patients with dyslipidaemia. Given that statin therapy for LDL-C
reduction has been shown to affect glycaemic control, it is import-
ant to assess effects of alirocumab on the development of new-
onset diabetes with regard to its safety profile as well as to yield
mechanistic insight on statin-induced diabetes.
Methods
Study design
The pooled analysis included 10 main ODYSSEY Phase 3 randomized,
double-blind, controlled trials (n ¼ 4974) with subcutaneous alirocumab
dosing every 2 weeks (Q2W) (24–102 weeks’ duration). Patients were
randomized to alirocumab, or to either placebo (LONG TERM
[NCT01507831], FH I [NCT01623115], FH II [NCT01709500], HIGH
FH [NCT01617655], COMBO I [NCT01644175]) or to ezetimibe
(COMBO II [NCT01644188], MONO [NCT01644474], OPTIONS I
[NCT01730040], OPTIONS II [NCT01730053], ALTERNATIVE
[NCT01709513]) as comparators (Supplementary material online, Table
S1). LONG TERM and HIGH FH utilized 150 mg Q2W from the outset
(Figure 1) and the other studies used alirocumab 75 mg Q2W with uptitra-
tion to 150 mg Q2W at Week 12 if LDL-C goals were not achieved at
Week 8 depending on CV risk. Treatment allocation was in addition to
maximally tolerated statin therapy in ODYSSEY LONG TERM, FH I, FH
II, COMBO I, COMBO II, and HIGH FH; in addition to commonly used sta-
tin doses which could be up-titrated in the OPTIONS I and II studies; and
there was no background statin in the MONO and ALTERNATIVE studies.
Intensity of statin doses across the pooled studies is provided in Figure 1.
Patients
All patients provided written informed consent and were aged ≥18
years. The MONO study included only patients with moderate CV
risk, based on European guidelines.19,20 The ALTERNATIVE study in-
cluded statin intolerant patients with moderate, high, or very high CV
risk and the remaining studies were in those at high or very high CV
risk (Figure 1; Supplementary material online, Table S1). Inclusion criteria
for baseline LDL-C were ≥1.8 mmol/L for those who had experienced
prior CV events or ≥2.6 mmol/L for those who had experienced no
prior experience of CV events with the exception of the HIGH FH
and LONG TERM study in which LDL-C had to be ≥4.14 mmol/L
and ≥1.8 mmol/L, respectively, for all individuals (Supplementary ma-
terial online, Table S1) at baseline.
Categorization of individuals into diabetes,
pre-diabetes, or normoglycaemia
Individuals were categorized as having diabetes, pre-diabetes, or being
normoglycaemic at baseline and follow-up. Four sources of data were
used: medical history data at baseline; treatment-emergent adverse events
(TEAEs); HbA1C, measured once during baseline and then measured at
Week 12, 24, 52, and 78; and FPG measured twice during the baseline
phase and at Week 12, 24, 36, 52, 64, and 78. The term pre-diabetes (as
per American Diabetes Association [ADA], guidelines)21 was used instead
of impaired glucose tolerance since evaluation of individuals for diabetes
and pre-diabetes status was performed using FPG/HbA1C measurements
and not oral glucose tolerance test measurements.
For the main analyses, diabetes at baseline was considered present if a
Custom Medical Dictionary for Regulatory Activities (MedDRA) Query
(CMQ) of the medical history reported ‘diabetes’. We considered this a
more specific definition than additionally including the baseline phase
FPG (≥7.0 mmol/L) or a single HbA1C (≥6.5%) measure to define base-
line diabetes but we also report sensitivity analyses using these labora-
tory measurements. As per the ADA 2015 Standards of Care, two
different tests above diagnostic threshold (such as HbA1C ≥6.5% and
FPG ≥7.0 mmol/L) confirms diagnosis of diabetes.22 The latter in-
creased the number of patients with diabetes at baseline from 1526
to 1636 (+7%: Supplementary material online, Table S2). Pre-diabetes
was defined as those assigned CMQ code ‘pre-diabetes’ recorded in
the medical history OR baseline HbA1C ≥5.7%, OR two values of
FPG (at screening and randomization) ≥5.6 mmol/L.
Definition of transition to diabetes or to
pre-diabetes during follow-up
Figure 1 details the definition but, in brief, transition to new-onset dia-
betes during follow-up in individuals without diabetes at baseline was
explored in two ways. The first analysis was of TEAEs based on the
CMQ ‘diabetes mellitus or diabetic complications’ which included Me-
dRA terms that refer to ‘high glucose or glycaemia’. New anti-diabetes
drug use was requested to be reported in TEAEs. Second, in order to
maximize the sensitivity for detecting transition to diabetes, additional
analyses were conducted for transition to diabetes based on two consecu-
tive values of FPG ≥7.0 mmol/L or two values of HbA1C ≥6.5% at least 2
months apart consistent with diabetes or a CMQ code for ‘diabetes’ but
excluding MedRA terms that refer to ‘high glucose or glycaemia’ (Figure 1).
Thirty-eight patients reported new diabetes drug use; all were captured as
transition to diabetes or pre-diabetes except three: two patients belonging
to alirocumab and one to the placebo group.
In the absence of transition to diabetes, transition to pre-diabetes
during follow-up in individuals with baseline normoglycaemia was de-
fined as having a TEAE report with CMQ code ‘pre-diabetes’ or two
consecutive values of FPG ≥5.6 mmol/L or two values of HbA1C
≥5.7% at least 2 months apart. Regression to normoglycaemia among
those with pre-diabetes at baseline was also quantified.
Additional sensitivity analysis of transition to
new-onset diabetes during follow-up
To account for HbA1C/FPG variability, a sensitivity analysis was per-
formed in which FPG and HbA1C were further required to have
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increased by a specified amount from baseline (Figure 1; Supplementary
material online, Methods). Post hoc we considered whether analyses al-
lowing two consecutive diagnostic values, one of FPG and one of HbA1C
to qualify as diabetes were warranted. However, this would have in-
creased the number of transitions very little; five individuals in the
placebo-controlled pool (two in placebo, three in alirocumab) and
one patient in the ezetimibe-controlled pool (one in alirocumab) and
so was not reported further.
Statistical methods
The safety population was defined as all randomized individuals who
received at least one full or partial dose of study drug. Data were
pooled into four groups: alirocumab and placebo from the placebo-
controlled trials; and alirocumab and ezetimibe from the ezetimibe-
controlled trials. The evaluation period was from the first dose of
study treatment up to the last injection plus 70 days (termed the
TEAE period). Follow-up time was up to transition to diabetes or, if
diabetes did not occur, on transition to pre-diabetes or else at the
end of the TEAE period. Occurrence of events of interest was sum-
marized using incidence rate, event rate per 100 patient-years, with
95% CI. The mid-P method was used to determine these CIs due to
the discrete distribution of the endpoint and the low number of
events.23 The HR was calculated using a Cox proportional hazards
model stratified on the study in order to compare treatment groups.
Effects on HbA1C and FPG measurements are presented using descrip-
tive statistics and graphs during the treatment period, i.e. up to 21 days
after the last injection. These data focus on the placebo-controlled
rather than ezetimibe-controlled studies as these had the longer
follow-up (median exposure of 78 weeks vs. 24–38 weeks in the
placebo-controlled vs. the ezetimibe-controlled studies, respectively).
These analyses were not right-censored for new diabetes drugs
initiation. SAS version 9.2 was used for the statistical analyses.
Figure 1 Schematic of population characteristics and study design. an values represent number of individuals in the safety analysis. bDose ad-
justment to 150 mg Q2W at Week 12 if LDL-C was not at goal by Week 8. cBackground statin was maximally tolerated dose in COMBO II, ator-
vastatin 20–40 mg in OPTIONS I, and rosuvastatin 10–20 mg in OPTIONS II and no statin in MONO and ALTERNATIVE. In addition, patients
were allowed to receive other LLT (except for ezetimibe in ezetimibe-controlled studies). Maximally tolerated statin was defined as high-dose
statin (atorvastatin 40–80 mg, rosuvastatin 10–20 mg, or simvastatin 80 mg daily), or lower doses with an investigator-documented reason, e.g.
intolerance. dAn individual not in diabetes or pre-diabetes category as defined above was considered normoglycaemic. Categorization of indivi-
duals at both baseline and follow-up was performed stepwise. eHbA1C was measured once during baseline. CMQ, Custom MedDRA Query; CV,
cardiovascular; FH, familial hypercholesterolaemia; FPG, fasting plasma glucose; HbA1C, glycated haemoglobin A1C; HeFH, heterozygous familial
hypercholesterolemia; LLT, lipid-lowering therapy; Q2W, every 2 weeks; TEAE, treatment-emergent adverse event.
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Results
Baseline categorization of individuals
related to their glycaemic status
The prevalence of diabetes, pre-diabetes, and normoglycaemia was
comparable between treatment groups in both placebo-controlled
and ezetimibe-controlled pools (Table 1). Overall, across the stud-
ies, 30.7% had diabetes, 39.6% had pre-diabetes, and 29.7% were
normoglycaemic. Demographic and baseline characteristics of indi-
viduals without diabetes at baseline for the randomized populations
of the 10 studies were similar within the pooled treatment groups
(Supplementary material online, Table S3). Median duration of aliro-
cumab exposure of individuals without diabetes at baseline in the
placebo-controlled pool was 78 weeks. In the ezetimibe-
controlled pool, median duration of exposure to study drug ranged
from 24 to 38 weeks (Supplementary material online, Table S4).
Overall, in individuals without diabetes at baseline, 63% received
alirocumab 150 mg Q2W (mostly derived from LONG TERM
where individuals were treated with a fixed dose of 150 mg
Q2W) and 37% were treated with alirocumab 75 mg Q2W. Cumu-
lative exposure for alirocumab vs. placebo was 2128.7 and 1078.2
patient-years, respectively; for alirocumab vs. ezetimibe, it was
474.6 and 292 patient-years, respectively (Supplementary material
online, Table S4) among this subset of patients without diabetes at
baseline. There was no difference between the treatment arms in
the dosage category or frequency of background statin usage during
the TEAE period (Supplementary material online, Figure S1).
Transition to diabetes based on
treatment-emergent adverse event data
alone
The transition to diabetes based solely on the TEAE terms among
those without diabetes at baseline is shown in Table 2. Overall, there
were 66 such transitions across the studies. There was no increase
in the incidence of diabetes, thus defined, in the alirocumab group
compared with controls with HR (95% CI) ¼ 0.64 (0.36–1.14) in
the placebo-controlled pool and 0.55 (0.22–1.41) in the ezetimibe-
controlled pool. The combined estimate across the two pools was
HR ¼ 0.62 (0.38–1.00).
Changes in mean fasting plasma glucose
and HbA1C measurements during
follow-up by treatment allocation
Mean HbA1C (Figure 2A) and FPG (Figure 2B) change from baseline
measures between different treatment groups compared with pla-
cebo control showed no meaningful difference in individuals with-
out diabetes at baseline. As shown in Figure 2, both HbA1C and
FPG varied slightly in both alirocumab and placebo groups over
the course of the studies. These variations seen in mean HbA1C
and FPG change from baseline were of similar magnitude in both
the alirocumab and placebo groups (0.04% and 0.05% for HbA1C
and 20.02 mmol/dL and 20.02 mmol/dL for FPG at the Week
78 visit, in alirocumab and placebo group, respectively). Minor var-
iations in biochemical parameters can occur during trials and em-
phasize the need for appropriate comparator groups. Such
individuals in the placebo-controlled pool were on background
maximally tolerated statin therapy (Figure 1). As shown in Supple-
mentary material online, Figure S2, there is no evidence of any signifi-
cant adverse effect of alirocumab compared with ezetimibe in the
very small number of participants not on background statins, in
the ezetimibe-controlled studies. Due to the small sample size,
the power to detect effects from these data is very limited.
Transition to diabetes based on combined
treatment-emergent adverse event and
fasting plasma glucose/HbA1C laboratory
data
Transition to new-onset diabetes and pre-diabetes using both the
TEAE data and the FPG and HbA1C data are shown in Table 3 and
further detailed in Supplementary material online, Table S5. Among
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Glycaemic categories at baseline in the pool of 10 Phase 3 studies
n (%) Placebo-controlled pool Ezetimibe-controlled pool
Placebo
(n 5 1174)
Alirocumab
(n5 2318)
Ezetimibe
(n5 618)
Alirocumab
(n5 864)
Diabetes as per medical history (excluded from further analysis)a 356 (30.3) 698 (30.1) 190 (30.7) 282 (32.6)
Pre-diabetesb 453 (38.6) 903 (39.0) 254 (41.1) 359 (41.6)
As per medical history 28 (2.4) 52 (2.2) 20 (3.2) 33 (3.8)
As per laboratory data only 425 (36.2) 851 (36.7) 234 (37.9) 326 (37.7)
As per HbA1C only 214 (18.2) 452 (19.5) 118 (19.1) 138 (16.0)
As per FPG only 64 (5.5) 141 (6.1) 47 (7.6) 57 (6.6)
Normoglycaemiac 365 (31.1) 717 (30.9) 174 (28.2) 223 (25.8)
aDiabetes at baseline is defined as those assigned CMQ code ‘diabetes’ recorded in the medical history.
bPre-diabetes defined as those assigned CMQ code ‘pre-diabetes’ recorded in the medical history OR baseline HbA1C ≥5.7%, OR two values of FPG (at screening and
randomization) ≥5.6 mmol/L. HbA1C was measured once during baseline.
cAn individual not in diabetes or pre-diabetes category as defined above was considered normoglycaemic. Categorization of individuals at baseline was performed stepwise.
CMQ, Custom MedDRA Query; FPG, fasting plasma glucose; HbA1C, glycated haemoglobin A1C.
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those with pre-diabetes at baseline, the majority remained in this
category during follow-up. Overall, 8.7% of these individuals transi-
tioned to new-onset diabetes and most progressions were based on
laboratory parameters rather than clinical TEAE reports (Supple-
mentary material online, Table S5). The HR (95% CI) for transition
associated with alirocumab was not significant in either placebo
(0.90 [0.63–1.29]) or ezetimibe (1.10 [0.57–2.12]) controlled pools
(Table 3). Among those with pre-diabetes at baseline, regression to
normoglycaemia was common but there was no difference between
alirocumab and control groups on this regression.
Among those categorized normoglycaemic at baseline, there
were no transitions to diabetes or pre-diabetes based on TEAEs
and just three transitions to new-onset diabetes all based on FPG
measurements (Supplementary material online, Table S5). Transi-
tion to pre-diabetes based on lab parameters was common across
all treatment groups - about one-third of all individuals in the
placebo-controlled pool and about one-quarter in the ezetimibe-
controlled pool (Supplementary material online, Table S5). The
HR (95% CI) for transition associated with alirocumab was not sig-
nificant for either the placebo (1.20 [0.96–1.49]) or ezetimibe (0.88
[0.59–1.32]) controlled pools (Table 3).
The sensitivity analysis, assessing the variability of HbA1C/FPG, did
not alter the conclusions. Similar and non-significant HRs for transi-
tion to new-onset diabetes or pre-diabetes in both treatment
groups was observed as for the main analyses (Supplementary ma-
terial online, Table S6).
A further sensitivity analysis of the transition to new-onset diabetes
further excluding those with baseline diabetes based also on labora-
tory baseline parameters rather than medical history alone did not
alter the conclusions (Supplementary material online, Table S7).
When analyses were restricted to the LONG TERM study in which
the higher fixed dose of alirocumab 150 mg Q2W was used, the con-
clusions were unchanged. Our analysis includes all those who re-
ceived at least one dose of drug. Discontinuation rates were low
and were balanced between the treatment arms. In the placebo
pool, the treatment discontinuation rate at 24 weeks was 7.7% in
both the alirocumab- and placebo-treated groups. In the ezetimibe
pool, the treatment discontinuation rate is 13.5% in the alirocumab-
treated group and 15.7% in the ezetimibe-treated group.
Regarding general safety across the ODYSSEY Phase 3 pro-
gramme in all 10 studies including individuals with and without dia-
betes, the percentage of individuals who experienced at least one
TEAE, at least one treatment-emergent serious adverse event,
and any TEAE leading to permanent treatment discontinuation
was similar between the alirocumab and control groups. Injection-
site reactions, influenza, and pruritus occurred more frequently in
individuals receiving alirocumab than control. These events were
transient and mild in intensity and did not necessitate treatment
discontinuation.
Discussion
In this pooled analysis of 10 Phase 3 studies from the ODYSSEY pro-
gramme, we found no evidence that alirocumab affects the inci-
dence of new-onset diabetes in 3448 individuals without diabetes
at baseline with a follow-up period of 6–18 months. Our study com-
prises all the available data to-date on transition to diabetes in the
ODYSSEY programme for the PCSK9 inhibitor alirocumab. Further
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Table 2 Transition to diabetes based on treatment-emergent adverse event data alone by treatment group
Placebo-controlled pool Ezetimibe-controlled pool
Placebo
(n5 818)
Alirocumab
(n5 1620)
Ezetimibe
(n 5 428)
Alirocumab
(n 5 582)
Incident diabetes mellitus or diabetic complications TEAE
n (%,95% mid-P CI) 21 (2.6, 1.6–3.8) 27 (1.7, 1.1–2.4) 9 (2.1, 1.0–3.8) 9 (1.5, 0.8–2.8)
Number of patients with an event per 100 patient-yeara (95% CI) 1.8 (1.1–2.8) 1.2 (0.8–1.7) 2.8 (1.3–5.4) 1.8 (0.8–3.4)
HR vs. control (95% CI)b 0.64 (0.36–1.14) 0.55 (0.22–1.41)
Diabetes mellitus or diabetic complications TEAE, n (%)
Diabetes mellitus or diabetic complications (CMQ) 21 (2.6) 27 (1.7) 9 (2.1) 9 (1.5)
Type 2 diabetes mellitus 13 (1.6) 21 (1.3) 2 (0.5) 5 (0.9)
Diabetes mellitus 4 (0.5) 4 (0.2) 2 (0.5) 2 (0.3)
Diabetic neuropathy 0 1 (,0.1) 0 0
Diabetic retinopathy 0 1 (,0.1) 0 0
Glucose tolerance decreased 0 1 (,0.1) 0 0
Blood glucose increased 1 (0.1) 0 3 (0.7) 1 (0.2)
Hyperglycaemia 3 (0.4) 0 2 (0.5) 1 (0.2)
MedDRA 17.1. The selection of preferred terms (PTs) is based on the CMQ ‘diabetes mellitus or diabetic complications’.
n (%) ¼ number and percentage of individuals with at least one event. Table sorted by decreasing incidence of PT in the alirocumab group of placebo-controlled pool. Individuals
without diabetes at baseline defined as those not assigned CMQ code ‘diabetes’ recorded in medical history.
aCalculated as number of individuals with an event divided by total patient years.
bCalculated using a Cox model stratified on the study.
CI, confidence interval; CMQ, Custom Medical Query; HR, hazards ratio; MedDRA, Medical Dictionary for Regulatory Activities; TEAE, treatment-emergent adverse event.
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data and longer follow-up are needed to conclusively rule out any
effect. However, so far there was no evidence of an effect of aliro-
cumab on transition to diabetes based on TEAEs related to diabetes
and diabetic complications (Table 2), or on a composite measure
combining TEAEs with threshold values for HbA1C or FPG (Table 3).
Neither was there evidence of any effect on transition from normo-
glycaemia to pre-diabetes. Transitions in both directions between
the normoglycaemic and pre-diabetes states were common. The
percent of those patients transiting to pre-diabetes from normogly-
caemia and the percent of patients regressing from pre-diabetes to
normoglycaemia were both higher for alirocumab than control-
treated pools but with no significant effects in either direction being
found. In contrast, a 9% increased risk for new-onset diabetes (odds
ratio [OR] 1.09; 95% CI 1.02–1.17) was associated with statin use in
a meta-analyses with 91 140 participants followed for an average of
4 years.5 In a subsequent analysis of five statin trials (n ¼ 32 752)
with a weighted mean (standard deviation [SD]) follow-up of 4.9
(1.9) years, intensive-statin therapy was associated with an increased
risk of new-onset diabetes compared with moderate-statin therapy
(OR 1.12, 95% CI 1.04–1.22).1 In the JUPITER trial where a similar
50% reduction in LDL-C to that reported in the placebo-controlled
studies here was seen, the HR for physician-reported diabetes was
1.25 overall. While our CI for the equivalent diabetes incidence
TEAEs are wide, they do exclude this estimate.
Figure 2 HbA1C (%) and fasting plasma glucose (mmol/L) trajectories (change from baseline) in those without diabetes at baseline: alirocumab
vs. placebo. Placebo-controlled studies: Phase 3 (LONG TERM, FH I, FH II, HIGH FH, COMBO I). At Week 12, HbA1C was measured only in the
LONG TERM. The last on-treatment value is defined as the last value collected up to 21 days after the last double-blind IMP injection. Patients who
had that parameter assessed at baseline and/or at follow-up are included. Individuals without diabetes at baseline defined as those not assigned
CMQ code ‘diabetes’ recorded in medical history. CMQ, Custom MedDRA Query; FPG, fasting plasma glucose; HbA1C, glycated haemoglobin
A1C; IMP, Investigational Medicinal Product; CI, confidence interval.
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Few of the previous studies on statins analyzing the risk of new-
onset diabetes have measured HbA1C or FPG serially during the
treatment period. We found no meaningful difference in effect of alir-
ocumab vs. comparator on changes in FPG or HbA1C when serially
measured in these studies of up to 78 weeks follow-up. In contrast,
a small but significant difference in HbA1C values was previously re-
ported in a comparatively larger rosuvastatin trial of .15 000 indivi-
duals at 24 months exposure.3,4 In the Collaborative Atorvastatin in
Diabetes (CARDS) trial, among individuals with diabetes at baseline,
atorvastatin 10 mg daily increased HbA1C by only 0.14% (95% CI
0.08–0.21) (1.5 mmol/mol [95% CI 0.8–2.3]) an effect that was
seen within the first year of exposure in 2739 participants.24
An important aspect of our analysis is that the majority of people
were already on background statin therapy. Around 54% of the in-
dividuals in our pooled analysis (n ¼ 4974) were receiving high-dose
background statin therapy, namely atorvastatin 40–80 mg, rosuvas-
tatin 20–40 mg, or simvastatin 80 mg daily. There were too few per-
sons in the trial programme not on any statin to examine incidence
of diabetes in this group separately (n ¼ 289 in the ezetimibe-
controlled studies from MONO and ALTERNATIVE).
The exact molecular mechanism by which statins impact glycaemic
control is not understood.10 The most recent meta-analysis of
129 170 trial participants observed the effect of statin on the inci-
dence of diabetes and reported an association with modestly in-
creased body weight but, unlike effects on glycaemia, was dose
independent.7 In that same study, a Mendelian randomization per-
formed with common variants of the 3-hydroxy-methylglutaryl coen-
zyme A reductase (HMGCR) gene indicated the association of certain
single nucleotide polymorphisms of HMGCR gene with type 2 dia-
betes, consistent with the glycaemic effects of statins resulting from
the downstream effects of HMGCR inhibition itself rather than an off-
target effect.7 A 6-year observational cohort study in 8749 partici-
pants reported decreases in insulin sensitivity and insulin secretion
associated in statin users.9 Others have postulated a lipotoxic effect
on the pancreatic b-cell due to increased accumulation of cholesterol
in the b-cell. Consistent with this, the prevalence of type 2 diabetes
was reduced in the presence of LDLR mutations in HeFH individuals
suggesting a causal relationship between LDLR-mediated transmem-
brane cholesterol transport and type 2 diabetes and inverse associa-
tions were found between type 2 diabetes incidence and LDL-C
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Table 3 Transition between glycaemic categories based on the treatment-emergent adverse event or laboratory data
by treatment groupa
Placebo-controlled pool Ezetimibe-controlled pool
Placebo
(n5 818)
Alirocumab
(n 5 1620)
Ezetimibe
(n 5 428)
Alirocumab
(n5 582)
Pre-diabetes at baseline, n/N1 (%)
Developed diabetesa 47/453 (10.4) 84/903 (9.3) 14/254 (5.5) 26/359 (7.2)
Remained with pre-diabetesa 342/453 (75.5) 663/903 (73.4) 162/254 (63.8) 237/359 (66.0)
Regressed to normoglycaemia 64/453 (14.1) 156/903 (17.3) 78/254 (30.7) 96/359 (26.7)
Analysis of transition from baseline pre-diabetes to new-onset diabetes (by TEAE or laboratory measurements)
n (%,95% mid-P CI) 47 (10.4, 7.8–13.4) 84 (9.3, 7.5–11.3) 14 (5.5, 3.2–8.9) 26 (7.2, 4.9–10.3)
Number of patients with an event/100 patient-yearb
(95% CI)
7.7 (5.6–10.2) 6.9 (5.5–8.5) 7.2 (3.9–12.1) 8.4 (5.5–12.3)
HR vs. control (95% CI)c 0.90 (0.63–1.29) 1.10 (0.57–2.12)
Normoglycaemic at baseline, n/N1 (%)
Developed diabetesa 1/365 (0.3) 1/717 (0.1) 0/174 1/223 (0.4)
Developed pre-diabetesa 115/365 (31.5) 261/717 (36.4) 42/174 (24.1) 59/223 (26.5)
Remained normoglycaemic 249/365 (68.2) 455/717 (63.5) 132/174 (75.9) 163/223 (73.1)
Analysis of transition from baseline normoglycaemic to pre-diabetes (by TEAE or laboratory measurements)
n (%,95% mid-P CI) 115 (31.5, 26.9–36.4) 261 (36.4, 32.9–40.0) 42 (24.1, 18.2–30.9) 59 (26.5, 21.0–32.5)
Number of patients with an event/100 patient-yearb
95% CI)
28.8 (23.8–34.6) 35.1 (31.0–39.7) 45.2 (32.6–61.1) 42.9 (32.6–55.3)
HR vs. control (95% CI)c 1.20 (0.96–1.49) 0.88 (0.59–1.32)
The number (n) represents the subset of the total number of individuals who met the criterion at least once during the TEAE period. The denominator (N1) for each parameter
within a treatment group is the number of individuals who had that parameter assessed at follow-up (not missing) during the TEAE period, by baseline glycaemic category. Diabetes
at baseline is defined using medical history. Pre-diabetes and diabetes at follow-up are defined using specific TEAE terms reported, raw values in HbA1C, and FPG (Figure 1).
MedDRA terms for high glucose or glycaemia were not included here since FPG and HbA1C are being directly queried.
aBreakdown of the basis of transition classification by TEAE or laboratory values in Supplementary material online, Table S5.
bCalculated as number of individuals with an event divided by total patient years.
cCalculated using a Cox model stratified on the study.
CI, confidence interval; FPG, fasting plasma glucose; HbA1C, glycated haemoglobin A1C; HR, hazards ratio; MedDRA, Medical Dictionary for Regulatory Activities; TEAE, treatment
emergent adverse event.
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levels in the Framingham Heart Study.25,26 Given the uncertainty re-
garding the underlying mechanism, an important question is whether
the increased risk of new-onset diabetes is an inevitable consequence
of LDL-C lowering with any drug class. A recent analysis of 18 144 in-
dividuals on background statin therapy in the IMPROVE-IT (IMProved
Reduction of Outcomes: Vytorin Efficacy International Trial) pro-
gramme, associated ezetimibe with a net 24% reduction in LDL-C
vs. placebo but found no difference in the new-onset of diabetes be-
tween groups.27 While this suggests that a glycaemic effect is not in-
evitable with LDL-C lowering, the question remains whether more
powerful LDL-C lowering agents, or those that increase LDL recep-
tor levels as statins and PCSK9 inhibitors do, will lead to a worsening
of glycaemia.
Accordingly, our data on the alirocumab trials to date are import-
ant in suggesting that PCSK9 inhibition may not lead to hypergly-
caemia. For evolocumab, another drug in the PCSK9 inhibitor
class, Blom et al. reported no significant effects on glycaemia in a
smaller dataset of 901 participants in the DESCARTES (Durable Ef-
fect of PCSK9 Antibody CompARed wiTh placEbo Study) trial fol-
lowed for 52 weeks28 and Henry et al. reported no effect on
glycaemia in 1104 participants over 52 weeks in the OSLER trial.29
A recent random-effects meta-analysis of randomized clinical trials
comparing the efficacy of evolocumab, placebo, and ezetimibe30
also found no evidence of evolocumab effect on glycaemic mea-
sures.30 Other sources of data on the effect of PCSK9 inhibition
on glycaemia have been inconclusive. In a recent Mendelian random-
ization analysis, Bonnefond et al. reported that the R46L
loss-of-function variant in the PCSK9 gene was associated with a
20.393 mmol/L lower LDL-C but was not associated with any al-
tered markers of glucose homeostasis or type 2 diabetes risk.31 An-
other study reported a difference of 10% vs. 6% in the combined
frequency of pre-diabetes and diabetes between carriers and non-
carriers of the PCSK9 InsLeu loss-of-function variant (P ¼ 0.04).32
Studies conducted in PCSK9-null mice investigating the role of the
protein on glycaemic control have also thus far yielded contradic-
tory results.33,34
In summary, pooled analysis from the Phase 3 ODYSSEY trial pro-
gramme for the PCSK9 inhibitor alirocumab shows no evidence of
an effect on diabetes incidence at this point despite the very sub-
stantial 40–60% LDL-C lowering achieved.12– 18 As effects of statin
on glycaemic control were not suggested until data from larger out-
comes studies were available, longer follow-up with a larger number
of individuals will be important to determine definitively the effect of
PCSK9 inhibitors on the development of diabetes. The ongoing
ODYSSEY OUTCOMES trial, randomizing 18 000 individuals
for 2–5 years follow-up capturing diabetes events, serial HbA1C,
and FPG measurements, will provide further data to establish
whether alirocumab has any effect on glycaemic measures.
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